Influence of long-term erythropoietin treatment on plasma levels of calcium-phosphate related hormones in haemodialyzed uraemic patients.
Exacerbation of secondary hyperparathyroidism (as manifested by calcium deposits and local inflammation in periarticular tissues) has been reported in haemodialyzed (HD) uraemic patients treated with recombinant human erythropoietin. However, short-term treatment with recombinant human erythropoietin (r-Hu EPO) did not influence significantly plasma levels of parathyroid hormone (PTH), calcitonin (CT) and 25-hydroxycholecalciferol (25-OHD3) in uraemic HD patients. The present study aimed to assess the effect of long-term r-Hu EPO therapy for 12 months on plasma PTH, CT, 25-OHD3 and 1,25-dihydroxycholecalciferol (1,25-(OH)2D3) in uraemic HD patients.
Kokot
F
F
Department of Nephrology, Silesian University School of Medicine, Katowice, Poland.
Wiecek
A
A
Marcinkowski
W
W
Schmidt-Gayk
H
H
Rudka
R
R
Trembecki
J
J
D000328:Adult; D000469:Alkaline Phosphatase / Q000097:blood; D002118:Calcium / Q000097:blood; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006728:Hormones / Q000097:blood*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011863:Radioimmunoassay; D011994:Recombinant Proteins / Q000627:therapeutic use; D012016:Reference Values; D006435:Renal Dialysis; D014511:Uremia / Q000097:blood* / Q000628:therapy*
D006728:Hormones; D011994:Recombinant Proteins; D004921:Erythropoietin; D000469:Alkaline Phosphatase; D002118:Calcium